CD4 News and Research

RSS

Study finds T cell response mostly conserved against SARS-CoV-2 Omicron variant following infection or vaccination

A new preprint examines the extent of protection offered by T cell responses to primary vaccination and/or natural infection with the virus.

11 Jan 2022

Immunological factors associated with impaired BNT162b2 mRNA vaccine response in older adults

A new study posted to the pre-print server medRxiv* investigated the significant immune alterations concerning SARS-CoV-2 specific innate and adaptive immunity associated with a lower BNT162b2 mRNA vaccine response in older individuals.

10 Jan 2022

Hybrid immunity shown to offer sub-optimal protection against SARS-CoV-2 Omicron variant

In a new study, researchers evaluated the neutralizing power of the vaccine against SARS-CoV-2 and vaccine plus infection-induced antibodies against the Omicron variant in a live virus neutralization assay.

10 Jan 2022

Mapping regulatory T-cell populations in COVID-19 patients

In a new study, researchers used mass spectrometry to investigate changes to immune systems, in particular regulatory T-cells (Tregs), in a large cohort of moderate, severe, and critical Japanese coronavirus disease 2019 (COVID-19) patients and healthy controls.

10 Jan 2022

SARS-CoV-2 viral mutations shown to have a limited effect on T cell immunity

New research suggests that viral mutations have a minimal effect on T cell immunity, which could explain the protection provided by vaccination against severe COVID-19, despite the significant loss of neutralizing antibodies.

10 Jan 2022

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

In a recently published article in the journal Cell Reports, scientists have demonstrated that individuals with or without a history of coronavirus disease 2019 (COVID-19) exhibit differential humoral and cellular immune responses 14 days after receiving mRNA-based COVID-19 vaccine developed by Pfizer/BioNTech. However, at a later time point, the responses become comparable between the two groups.

9 Jan 2022

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

In a new study, researchers determined CD8+ and CD4+ T cell responses against the SARS-CoV-2 Omicron variant in 51 individuals vaccinated with the messenger ribonucleic acid (mRNA)-based Pfizer and adenovirus vector-based Johnson & Johnson vaccines.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

In a new study, a team of researchers from multi-national institutions discovered that 70-80% of CD4 and CD8 T cell responses to spike were consistent across research groups. Moreover, although having far more mutations, the magnitude of Omicron cross-reactive T cells was comparable to that of the Beta and Delta variants.

3 Jan 2022

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

The advent of the B.1.1.529 (Omicron) severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) variant, detected initially in Botswana and South Africa and now found in over 135 countries as of January 3, 2022, has sparked fears of a new global wave of infections and hospitalizations

3 Jan 2022

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Researchers ascertain whether the SARS-CoV-2 Omicron variant evades cellular immunity.

3 Jan 2022

Omicron infection induces cross-reactive immune responses

New research revealed that vaccine-breakthrough infections might elicit cross-reactive bNAbs against all variants of concern.

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

A team of international scientists has recently revealed that T cell responses induced by coronavirus disease 2019 (COVID-19) vaccines are able to cross-recognize different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study is currently available on the bioRxiv* preprint server.

30 Dec 2021

Reviewing myocarditis and pericarditis in immunosuppressed individuals following COVID-19 mRNA vaccination

A new study did not conclusively correlate the incidence of myocarditis or pericarditis with mRNA vaccination against SARS-CoV-2.

30 Dec 2021

Exploring the importance of selenium in COVID-19 patients

In a new study, researchers reviewed research on the role that selenium could play in protecting individuals against coronavirus disease 2019.

29 Dec 2021

Exploring why children have milder COVID-19 infections compared to adults

A new study has revealed that an activated pre-exposure innate interferon response in airways together with significantly reduced systemic interferon-stimulated populations are associated with relatively milder severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children.

23 Dec 2021

T-cell response to Omicron after an mRNA COVID vaccine booster

In a recent prospective observational study posted to the medRxiv* preprint server, researchers determined Omicron variant-associated T cell responses before and after a third dose of messenger ribonucleic acid (mRNA) vaccination against coronavirus disease (COVID-19) in anti-CD20-treated multiple sclerosis (MS) patients.

22 Dec 2021

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Researchers developed four distinct recombinant vesicular stomatitis virus (rVSV)-based bivalent vaccines against SARS-CoV-2 and influenza virus.

22 Dec 2021

Effect of T cell reactivity in COVID-19 infection and vaccination

Researchers recently developed an immunodiagnostic T cell assay to classify T cell immune responses of the subjects based on their coronavirus disease 2019 infection and vaccination history.

21 Dec 2021

CD4 News and Research

Study finds T cell response mostly conserved against SARS-CoV-2 Omicron variant following infection or vaccination

Immunological factors associated with impaired BNT162b2 mRNA vaccine response in older adults

Hybrid immunity shown to offer sub-optimal protection against SARS-CoV-2 Omicron variant

Mapping regulatory T-cell populations in COVID-19 patients

SARS-CoV-2 viral mutations shown to have a limited effect on T cell immunity

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

Exploring vaccine-induced cellular immunity against SARS-CoV-2 Omicron variant

Transplant recipients benefit from a COVID-19 vaccine booster

SARS-CoV-2 spike T cell responses from vaccines or infection remain robust against Omicron

Very high rates of asymptomatic infection with Omicron compared to prior SARS-CoV-2 variants

T-cell responses to SARS-CoV-2 Omicron variant confer protection to vaccinated individuals

Omicron infection induces cross-reactive immune responses

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

Vaccine-induced T-cells vs. Omicron well preserved compared with all variants

Reviewing myocarditis and pericarditis in immunosuppressed individuals following COVID-19 mRNA vaccination

Exploring the importance of selenium in COVID-19 patients

Exploring why children have milder COVID-19 infections compared to adults

T-cell response to Omicron after an mRNA COVID vaccine booster

rVSV-based bivalent vaccine against SARS-CoV-2 delta variant and influenza

Effect of T cell reactivity in COVID-19 infection and vaccination

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News